SAN FRANCISCO -- Genomic tests to help guide treatment decisions for prostate cancer frequently pointed in different directions when used to evaluate the same patient, a small retrospective study ...
Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate ...
TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help ...
After months of delay, the Medicare Administrative Contractor (MAC), with jurisdiction over most molecular diagnostic tests used to treat cancer, made a series of decisions this fall that will allow ...
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
SALT LAKE CITY, Utah, May 20, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual ...
SALT LAKE CITY, June 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results